The c-Jun amino-terminal kinase (JNK) pathway is activated by a wide variety of immunological and stress stimuli, including: pro-inflammatory cytokines (tumor necrosis factor-a (TNF-a), interleukin-1), Toll-like receptor signaling by exogenous and endogenous ligands (endotoxin and heatshock proteins), growth factors (angiotensin II, transforming growth factor-b1), oxidative stress, and osmotic shock. 1 These stimuli induce a cascade of kinase phosphorylation events, leading to the dual phosphorylation of the Thr-X-Tyr activation motif of JNK. The active (phosphorylated) form of JNK can then phosphorylate-specific target proteins, mostly transcription factors, to modulate gene transcription resulting in a variety of cellular responses, including: production of pro-inflammatory molecules; modulation of cell differentiation, proliferation, and apoptosis. 1 A feature of JNK is that it is the only known kinase that phosphorylates Ser63 and Ser73 in the NH 2 -terminal activation domain of c-Jun. [2] [3] [4] [5] Thus, detection of c-Jun phosphorylation at these residues can be used as a read-out of JNK activity. Indeed, c-Jun is an important target of JNK signaling, as, when phosphorylated, it can combine with c-fos to form the transcription factor, AP-1, which promotes transcription of pro-inflammatory molecules such as interleukin-1b, monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1. 6 There are three genes encoding closely related JNK enzymes, termed JNK1-3. 1 Although Jnk1 (Mapk8) and Jnk2 (Mapk9) are widely expressed in most cell types, including the kidney, Jnk3 (Mapk10) is restricted to the nervous system, heart, and testes. Furthermore, alternative RNA splicing results in the production of up to 10 different JNK isoforms of approximately 46 and 54 kDa. 7 The widespread expression of both Jnk1 and Jnk2 can make it difficult to define functional roles for this pathway due to redundancy in signaling, and the finding that combined genetic deficiency for Jnk1 and Jnk2 is fetal lethal.
JNK signaling plays a role in the immune response. Specific functions for Jnk1 and Jnk2 have been described in the differentiation of naïve T cells into T-helper type 1 effector cells, [8] [9] [10] although the role of JNK signaling in the secondary immune response has not been investigated. In addition, in vitro studies have shown that endotoxininduced nitric oxide production and that Fcg-receptor activation induced TNF-a production by macrophages is dependent upon JNK signaling. 11, 12 Furthermore, administration of a JNK inhibitor drug has been shown to inhibit joint inflammation and erosion in rat adjuvant-induced arthritis. 13 Activation of JNK signaling has been identified in a number of experimental models of immune-mediated kidney disease including rat anti-glomerular basement membrane (GBM) glomerulonephritis and passive Heymann's nephritis, [14] [15] [16] as well as in models of renal injury induced by nonimmune insults. [17] [18] [19] It is known that macrophages are critical effector cells in causing both acute and progressive renal injury in experimental models of anti-GBM disease. 20, 21 Furthermore, modulation of macrophage activation can have a substantial impact upon renal injury. 22, 23 We previously investigated the role of JNK signaling in an adoptive transfer model in which ex vivo JNK inhibition was shown to suppress macrophage-induced acute renal injury. 24 However, it remains to be determined whether: (i) JNK signaling is important in progressive immune-mediated renal injury and (ii) JNK blockade modulates the individual components of the renal immune response.
The primary aim of this study was to determine whether therapeutic targeting of JNK signaling, via systemic administration of a JNK inhibitor, can suppress acute and progressive glomerular and tubulointerstitial damage in immune-mediated kidney disease. The secondary aim of this study was to determine whether systemic inhibition of JNK signaling modulates the various components of the renal immune response in terms of neutrophils, macrophages, T cells, and the humoral response. To achieve these aims, we used a specific JNK inhibitor, CC-401, to treat a rat model of anti-GBM glomerulonephritis.
RESULTS

JNK activation in normal kidney and in acute anti-GBM disease
In normal rat kidney, Western blotting shows a weak signal for phosphorylated JNK (p-JNK) in glomeruli (Figure 1a) , whereas immunostaining localizes p-JNK to parietal epithelial cells of Bowman's capsule (Figure 2a ) and occasional podocyte-like cells within the glomerular tuft. A marked increase in JNK phosphorylation is evident on day 1 of anti-GBM disease (Figure 1a) , with many p-JNK þ cells seen within the glomerular tuft (Figure 2d ). Direct evidence of JNK signaling can be derived from phosphorylation of c-Jun at Ser63, a specific JNK target. c-Jun is not expressed in normal rat kidney, except for occasional parietal epithelial cells, but c-Jun is rapidly induced in anti-GBM disease ( Figure 2 ). Western blotting demonstrates phosphorylation of c-Jun at Ser63 in glomeruli on day 1 of anti-GBM disease (Figure 1a) , while immunostaining identifies glomerular cells positive for p-c-Jun Ser63 immunostaining (Figure 2f ). Double immunostaining identified p-c-Jun Ser63 staining in many ED1 þ macrophages and in some cells of a podocyte morphology (Figure 3 ).
CC-401 inhibits JNK activation in acute anti-GBM disease
CC-401 is a specific inhibitor of the JNK signaling pathway, which has been described in detail. 19, 25 CC-401 inhibits JNK signaling by competitive binding to the adenosine triphosphate-binding site in the active, phosphorylated, form of JNK, resulting in inhibition of the phosphorylation of JNK targets, such as the amino-terminal activation domain of the transcription factor, c-Jun. Two initial experiments were performed in which CC-401 was administered to rats at 100 or 200 mg/kg bid, beginning 2 h before injection of anti-GBM serum with animals killed at 24 h. Western blot analysis (performed only in the 200 mg/kg dose experiment) showed that CC-401 treatment virtually abrogated phosphorylation of c-Jun at Ser63 (Figure 1a and b) . In contrast, CC-401 had no effect upon phosphorylation of JNK (Figure 1a and c) , as expected. CC-401 had no effect upon phosphorylation of the closely related kinases, p38 and ERK (Figure 1 ), indicating that the drug did not affect the activity of any up-stream kinases in these pathways. Immunostaining was performed in both experimental groups and the results are shown in Figure 2 . Consistent with Western blotting analysis, treatment of anti-GBM disease with 100 mg/kg CC-401 abrogated the presence of glomerular immunostaining for p-c-Jun Ser63, although glomerular cells stained for p-JNK were still evident ( Figure 2 ). 
CC-401 inhibits renal injury in acute anti-GBM disease
This disease model features moderate to heavy proteinuria within 24 h of injection of anti-GBM serum. In separate experiments, both doses of CC-401 treatment resulted in substantial protection from proteinuria (Figure 4a and b) . Administration of 100 mg/kg CC-401 produced peak blood drug levels of 1.8770.69 mM. This was in the target range of 1-3 mM peak drug blood levels and this dose was effective in suppressing JNK signaling. Therefore, all subsequent studies and analysis used CC-401 treatment at a dose of 100 mg/kg.
Induction of anti-GBM disease at 24 h was associated with glomerular infiltration of ED1 þ macrophages and R73 þ T cells, and upregulation of renal gene expression for the pro-inflammatory molecules; TNF-a, inducible nitric oxide synthase (iNOS), and MCP-1 (Figure 5a-e) . CC-401 treatment resulted in a partial reduction in glomerular macrophage accumulation, but had no effect upon glomerular T-cell infiltration (Figure 5a and b) . The increase in renal TNF-a and MCP-1 gene expression in anti-GBM disease was prevented by CC-401 treatment, whereas the increase in iNOS messenger RNA (mRNA) levels -which are very low in normal kidney -were only partially suppressed by CC-401 treatment ( Figure 5 ).
JNK blockade does not affect glomerular neutrophil influx in acute anti-GBM disease
Both neutrophils and macrophages contribute to the induction of proteinuria during the first 24 h in this model of anti-GBM disease. 20, 26 Glomerular neutrophil influx peaks at 3 h after anti-GBM serum injection and is largely resolved by 24 h. Therefore, we performed a separate experiment to examine the effect of JNK blockade on neutrophil recruitment. A prominent neutrophil influx was evident 3 h after anti-GBM serum injection in untreated animals versus normal controls (Figure 6a and b) . In addition, glomerular cells positive for p-c-Jun Ser63 were seen at 3 h (Figure 6e ), although this was substantially less than the number of infiltrating neutrophils. Treatment with CC-401 had no effect upon glomerular neutrophil accumulation ( Figure 6 ). The efficacy of CC-401 treatment was confirmed by the abolition of glomerular staining for p-c-Jun Ser63 (Figure 6f) , and achieving serum CC-401 levels of 1.7870.72 mM.
JNK blockade prevents progressive renal injury in rat anti-GBM disease
To determine whether the beneficial effects of CC-401 treatment could be sustained beyond the initial injury, we performed a study in which 100 mg/kg bid CC-401 treatment was begun 2 h before injection of anti-GBM serum injection and continued until animals were killed 14 days later. Untreated and vehicle-treated anti-GBM disease exhibited heavy proteinuria during the first 24 h of disease and this was sustained for the 14-day period, leading to a marked reduction in serum albumin levels (Figure 7a 
Effect of JNK blockade upon the immune response in anti-GBM disease
The development of glomerular and tubulointerstitial lesions on day 14 of anti-GBM disease in untreated and vehicletreated groups was associated with a significant interstitial T-cell infiltrate, whereas glomerular T cell numbers were not different to normal by this time point (Figure 9c and d) , consistent with previous studies in this model. 27 CC-401 treatment caused a significant reduction in interstitial T-cell accumulation (Figure 9d) , consistent with the overall reduction in tubulointerstitial injury seen with drug treatment. To analyze the effector T-cell response, we performed a 24 h skin delayed-type hypersensitivity response to an intradermal challenge with sheep immunoglobulin (Ig)G. Untreated and vehicle-treated anti-GBM disease groups had a significant increase in skin thickness in response to challenge with sheep IgG (1.5770.35 and 1.3870.59 mm, respectively) and this response was not significantly altered by CC-401 treatment (1.1770.51 mm; P ¼ not significant versus vehicle and no treatment groups).
On day 14 of anti-GBM disease, immunofluorescence staining identified glomerular deposition of sheep anti-rat GBM antibodies, rat IgG and C3, and this was not affected by CC-401 treatment (data not shown). As an additional assessment of the humoral immune response, we measured the serum titer of rat IgG antibodies against sheep Ig. The serum levels of total rat IgG against sheep Ig were significantly increased in CC-401-treated animals. Further analysis showed that the serum levels of the IgG1, IgG2a, and IgG2b subclasses of rat anti-sheep Ig were increased, although the increase in IgG1 failed to reach significance compared with the no treatment group (Figure 9e-h ). This increase in serum levels of rat anti-sheep IgG may simply reflect a reduced level of urinary loss of serum proteins in the CC-401-treated animals. Data from CC-401, vehicle, and no treatment groups on day 14 of anti-GBM disease (n ¼ 34) were pooled and analyzed using the Pearson single correlation coefficient. A significant negative correlation was seen between the degree of proteinuria and the serum titer of rat anti-sheep total IgG and the IgG1, IgG2a, and IgG2b subclasses (all Po0.05). Similarly, when examining the CC-401-treated group alone (n ¼ 14), a significant negative correlation was seen between the degree of proteinuria and the serum titer of rat anti-sheep total IgG and the IgG1 and IgG2b subclasses (all Po0.05), except for IgG2a (P ¼ 0.053).
The prominent glomerular macrophage infiltrate seen on day 14 of anti-GBM disease was unaltered by CC-401 treatment (Figure 9a) , despite a substantial reduction in glomerular lesions. In contrast, the substantial macrophage accumulation seen in the tubulointerstitium in vehicle and untreated anti-GBM disease was prevented by CC-401 treatment (Figure 9b ), in line with the reduction in tubulointerstitial damage.
Consistent with the 24 h study, CC-401 treatment prevented the increase in renal mRNA levels for TNF-a and MCP-1, while markedly reducing iNOS mRNA levels ( Figure  10 ). The increase in transforming growth factor-b1 mRNA levels seen on day 14 of anti-GBM disease was also prevented by CC-401 treatment (Figure 10d) . This model of anti-GBM disease features a transient glomerular neutrophil influx in the first few hours after administration of anti-GBM serum, which promotes the acute induction of proteinuria. 26 Immunostaining indicated that few neutrophils show JNK activation. The ability of CC-401 treatment to suppress acute proteinuria was not due to a reduction in the transient neutrophil influx seen at the 3 h time point. An effect of CC-401 on neutrophil function cannot be ruled out, but this appears unlikely based upon previous studies showing that JunD is the only Jun family member expressed in neutrophils, 28 and that JunD is considered a negative regulator of c-Jun function. 29 However, even if CC-401 did suppress acute renal injury via an effect upon neutrophil function, this could not account for the ongoing suppression of progressive anti-GBM disease seen with CC-401 treatment, as previous studies have shown that proteinuria and glomerular lesions develop rapidly in the face of sustained neutrophil depletion, which abrogates the acute phase of renal injury. 26 Macrophages are critical effector cells in causing both acute and progressive renal injury in experimental models of anti-GBM disease. 20, 21 Modulation of macrophage activation can have a substantial impact upon renal injury. 22, 23 We have previously demonstrated that inhibition of JNK signaling suppresses macrophage iNOS and TNF-a production in vitro. 24 Furthermore, ex vivo inhibition of JNK signaling can suppress macrophage-mediated renal injury in an adoptive transfer model of acute anti-GBM disease. 24 This study supports these findings and provides substantial new information. First, JNK signaling was shown to be prominent in glomerular macrophages in anti-GBM disease on the basis of immunostaining. Second, data in this study suggest that the main mechanism by which administration of CC-401 treatment suppressed acute and progressive anti-GBM disease was through inhibition of macrophage activation (see below), arguing that oral administration of a JNK inhibitor can effectively target macrophage function. This conclusion is based upon the marked reduction in iNOS and TNF-a mRNA levels and the reduction in glomerular lesions seen with CC-401 treatment, despite the lack of effect upon glomerular macrophage accumulation.
Previous studies have shown that macrophages are the major, if not the only, cell type responsible for iNOS expression in the injured kidney. [30] [31] [32] [33] [34] Thus, the substantial reduction in iNOS mRNA levels seen with CC-401 treatment of anti-GBM disease is evidence that inhibition of JNK signaling can suppress macrophage activation in vivo. However, it is not clear whether this reduction in iNOS mRNA levels contributes to the protection against renal injury with CC-401 treatment, as the pathogenic role of iNOS in anti-GBM disease remains controversial. 35 It is known that macrophages are a potent source of TNF-a in the injured kidney, although other intrinsic renal cell types including podocytes and tubular epithelial cells can also express TNF-a. [36] [37] [38] However, leukocyte-depletion studies have shown that the increase in glomerular TNF-a production in anti-GBM disease is macrophage dependent. 39 Thus, the ability of CC-401 treatment to prevent upregulation of renal TNF-a mRNA levels in anti-GBM disease is another argument that inhibition of JNK signaling can suppress macrophage activation in vivo. Furthermore, blocking studies have demonstrated a pathological role for TNF-a in promoting renal injury in this model of rat anti-GBM disease, 40 indicating that suppression of renal TNF-a gene expression is likely to be one mechanism by which CC-401 treatment inhibited renal injury.
The finding that glomerular macrophage numbers at day 14 of anti-GBM disease were unaltered with CC-401 treatment despite a substantial reduction in glomerular lesions is consistent with blockade of JNK signaling modifying macrophage function. This result extends previous findings in which ex vivo JNK blockade did not prevent glomerular macrophage accumulation, but did reduce acute macrophage-mediated renal injury. 24 JNK blockade did not appear to affect glomerular endothelial cell activation on the basis that both acute neutrophil and T-cell influx and the progressive glomerular macrophage accumulation were unaffected, although this issue has not been examined in the present study. The inability of JNK blockade to affect glomerular macrophage accumulation day 14 of anti-GBM disease despite preventing upregulation of MCP-1 mRNA levels is consistent with the development of glomerular macrophage infiltration in anti-GBM disease in MCP-1 (Ccl2) gene-deficient mice, 41 although antibody-based MCP-1 blockade has shown a partial reduction of glomerular macrophage numbers in anti-GBM disease. A striking finding in this study was that JNK inhibition prevented tubulointerstitial infiltration of macrophages and T cells despite prominent glomerular macrophage accumulation on day 14 of anti-GBM disease. Time-course studies have established that glomerular injury precedes tubulointerstitial damage in the progression of accelerated rat anti-GBM glomerulonephritis. 27 Given that the deposition of sheep Ig is limited to the GBM, it is thought that indirect activation of tubular cells by glomerular cytokine secretion and/or increased protein levels in the urinary space, causes upregulation of chemokines and adhesion molecules by tubular cells leading to the recruitment and activation of macrophages and T cells. 43 The ability of CC-401 treatment to prevent tubulointerstitial leukocyte infiltration is most likely due to suppression of tubular cell activation as a result of inhibition of glomerular inflammation and cytokine production (via inhibition of macrophage activation as discussed above) and the reduction in proteinuria. Indeed, this postulate is supported by the finding that JNK blockade prevented upregulation of renal MCP-1 mRNA levels on day 14 when MCP-1 is predominantly expressed by tubules. 41, 44 It has previously been shown that tubular MCP-1 is essential for tubulointerstitial macrophage infiltration in anti-GBM disease. 41, 44 T cells play a critical role in directing immune-mediated renal injury in progressive anti-GBM disease. 45, 46 However, CC-401 did not appear to affect the T-cell response in anti-GBM disease given the lack of effect of JNK blockade on acute glomerular T-cell recruitment and in the skin delayedtype hypersensitivity response. It is presumed that the reduction in interstitial T cells on day 14 of anti-GBM disease seen with CC-401 treatment simply reflects the lack of tubulointerstitial damage resulting from reduced proteinuria and cytokine production. Studies in gene knockout mice have shown that JNK1 is important in the primary immune response in which naïve T cells differentiate into T-helper type 1 cells. 8, 9 In this study, JNK blockade with CC-401 did not change the relative proportions of the IgG isotypes in the rat response to sheep Ig, suggesting that the T-helper type 1 response was unaltered. One reason for the lack of effect of JNK blockade upon the T-cell response may be that drug treatment did not begin until the time of the secondary antigen challenge when the primary immune response was already established. Thus, this study argues that JNK signaling is not required for the secondary T-cell response, an issue not previously examined in renal or non-renal disease.
JNK blockade caused an increase in serum levels of rat IgG against the immunizing antigen, suggesting that JNK signaling may modulate the humoral immune response. There are two possible mechanisms by which this may operate. First, it is known from in vitro studies that JNK activation can cause plasma-cell apoptosis. 47, 48 Thus, inhibiting B-cell and plasma-cell apoptosis by JNK blockade could potentially increase the production of rat anti-sheep IgG in the immune response. Second, the reduction in the degree of proteinuria seen with CC-401 treatment may contribute to protection against urinary loss of serum Igs. This potential mechanism is supported by the significant correlation between serum levels of rat anti-sheep IgG and the degree of proteinuria on day 14 of anti-GBM disease, which is also apparent in the CC-401-treated group when analyzed separately. However, further studies are required to define precisely the mechanisms responsible for increased serum rat anti-sheep IgG titers in the CC-401-treated animals.
In summary, this study has demonstrated a pathological role for JNK signaling in acute and progressive rat anti-GBM glomerulonephritis. These protective effects were associated with inhibition of macrophage activation, whereas the neutrophil influx and the acquired immune response did not appear to be affected. JNK inhibitors may be a novel therapeutic approach for the treatment of human glomerulonephritis.
MATERIALS AND METHODS Antibodies
The following rabbit antibodies against: phospho-JNK (Tyr183/ Tyr185); c-Jun; phospho-c-Jun (Ser63); phospho-p44/42 mitogenactivated protein kinase (Thr202/Tyr204); and phospho-p38 (Thr180/Tyr182) were obtained from Cell Signaling (San Deigo, CA). Other antibodies used were: rabbit anti-a1 tubulin (Abcam, Cambridge, MA), mouse anti-CD68-recognizing rat macrophages (ED1), and mouse anti-rat T-cell receptor (R73) (Serotec, Oxford UK); RP-1-recognizing rat neutrophils (Becton Dickinson, San Diego, CA); mouse anti-vimentin (Dako, Glostrup, Denmark); and fluorescein isothiocyanate-conjugated rabbit antibodies to rabbit IgG, rat IgG, and rat C3 (Sigma-Aldrich, Castle Hill, NSW, Australia). Secondary antibodies included: biotinylated goat antirabbit IgG, biotinylated rabbit anti-goat IgG, biotinylated goat antibodies reactive with mouse IgG1, IgG2a, and IgG2b isotypes and total IgG, and streptavidin-conjugated horseradish peroxidase (all from Zymed-Invitrogen, Carlsbad, CA). Horseradish peroxidaseconjugated goat anti-mouse IgG, mouse peroxidase-conjugated anti-peroxidase complexes, alkaline phosphatase-conjugated goat anti-mouse IgG, and mouse alkaline phosphatase-conjugated antialkaline phosphatase complexes (all from Dako).
Animals
Sprague-Dawley rats were obtained from Monash Animal Services, Clayton, Australia. All animal experimentation was approved by the Monash Medical Centre Animal Ethics Committee.
Western blot analysis
Glomeruli were isolated by differential sieving and then lysed in SDS-PAGE sample buffer, boiled, centrifuged, and the supernatant recovered. Samples were separated by SDS-PAGE, electroblotted onto nitrocellulose membranes, incubated with Blocking Buffer (LiCor Biosciences, Lincoln, NE) for 1 h, and then incubated with primary antibody overnight at 41C. Blots then were washed and incubated with Alexa Fluor 680 goat anti-rabbit IgG (Molecular Probes Inc., Eugene, OR) for 30 min and analyzed by the Odyssey infrared imaging system (LiCor Biosciences). Blots were reprobed for tubulin as a loading control. Results were quantified using the Gel-Pro Analyzer program (Media Cybernetics, Silver Springs, MD, USA).
CC-401
The specific JNK inhibitor CC-401, a newer generation inhibitor than SP600125, was synthesized by Celgene (San Diego, CA) and has been characterized previously. 19, 25 It is a potent inhibitor of all three forms of JNK (K i of 25-50 nM), and has at least 40-fold selectivity for JNK compared with other related kinases, including: p38, ERK, IKK2, PKC, Lck, and ZAP70. CC-401 acts to inhibit JNK signaling by competitive binding to the adenosine triphosphate-binding site in the active, phosphorylated, form of JNK, resulting in inhibition of the phosphorylation of JNK targets, such as the amino-terminal activation domain of the transcription factor, c-Jun. In cell-based assays, 1-5 mmol/l CC-401 provides specific JNK inhibition. CC-401 is prepared in a sodium citrate vehicle and administered to rats by twice daily gavage. Serum levels of CC-401 were analyzed by highpressure liquid chromatograph.
CC-401 treatment of anti-GBM glomerulonephritis
Passive accelerated anti-GBM disease was induced in male Sprague-Dawley rats (130-160 g) as described previously. 26 Briefly, rats were immunized by subcutaneous injection of 5 mg of sheep IgG in Freunds complete adjuvant followed 5 days later (termed day 0) by a tail vein injection of 5 ml/kg sheep anti-rat GBM serum. In all of the studies, CC-401 or vehicle treatment was begun 2 h before anti-GBM serum administration and continued twice daily thereafter until animals were killed. Three separate studies were performed in which animals were killed at 3 h (n ¼ 6 or 7), 24 h (n ¼ 6 or 7), or 14 days (n ¼ 14 for CC-401, n ¼ 11 for vehicle treated and n ¼ 10 for no treatment) after anti-GBM serum administration. Animals were housed in metabolic cages for 22 h to collect urine on days 1, 7, and 14. Blood was collected at the time of death. In the day 14 study, a skin delayed-type hypersensitivity response was examined. Twenty-four hours before being killed, each animal was given three separate intradermal injections of 0.1 ml each of sheep IgG (1 mg/ml), rabbit IgG (1 mg/ml), and normal saline. Skin thickness at the site of injection was measured using engineer's calipers at the time of killing by an investigator blinded to the treatment regimen. Analysis of serum creatinine and urinary protein were performed by the Department of Biochemistry, Monash Medical Centre.
Renal histology
Paraffin sections (2 mm) of methylcarn-fixed tissue were stained using PAS and hematoxylin. In the 14-day anti-GBM disease model, glomerular lesions were analyzed under high power ( Â 400) on PAS-stained sections. Each glomerulus within the section was scored. Glomerular lesions were defined by hyalinosis, focal and segmental adhesions, fibrinoid necrosis, and glomerular atrophy. Grading was based on the proportion of the glomerulus that had these lesions: 0, no damage; 1 þ o10%; 2 þ 10-25%; 3 þ 25-50%; 4 þ 450%. Tubulointerstitial lesions were assessed on the basis of tubular dilatation, atrophy, necrosis, protein casts, and mononuclear cell infiltration. The percentage of the cortex involved in tubulointerstitial lesions was scored as: 0, no damage; 1 þ o10%; 2 þ 10-25%; 3 þ 25-50%; 4 þ 450%. Scoring was performed on blinded slides.
Immunohistochemistry
Immunoperoxidase staining for p-JNK, c-Jun, p-c-Jun Ser63, vimentin, and ED1 þ macrophages was performed on 4 mm sections of formalin-fixed tissue using antigen retrieval (microwave oven heating in 0.1 M sodium citrate pH6.0 for 10 min) followed by a three-layer avidin-biotin peroxidase complex staining method. 49 Immunoperoxidase staining for R73 þ T cells and RP1 þ neutrophils used frozen sections of tissue fixed in 2% paraformaldehydelysine-periodate with a three-layer peroxidase anti-peroxidase method. Two color immunostaining used formalin sections in which p-c-Jun Ser63 þ cells were stained using the avidin-biotin peroxidase complex peroxidase-based method, followed by staining for ED1 þ macrophages using an alkaline phosphatase-conjugated anti-alkaline phosphatase method with Fast-Blue substrate development as described previously. 50 Quantification of immunostaining Glomerular accumulation of RP1 þ neutrophils was analyzed under high power ( Â 400) in 50 glomeruli per animal by image analysis using Image-Pro software (Media Cybernetics) and expressed as a percentage of the glomerular tuft area. Tubular vimentin immunostaining was quantified by scoring tubules in Â 250 fields. A positive tubule cross-section was defined as having two or more stained cells. All tubules in the cortex were assessed for each animal. The number of glomerular ED1 þ macrophages and R73 þ T cells were counted under high power ( Â 400) in 50 glomeruli per animals. Interstitial ED1 þ and R73 þ cells were counted in the entire cortex using high power fields ( Â 400). All scoring was performed on coded slides.
Real-time reverse transcription-polymerase chain reaction Total RNA was extracted from whole kidney samples using the RiboPure reagent (Ambion Inc., Austin, TX) and reverse transcribed using the Superscript First-Strand Synthesis kit (Invitrogen, Carlsbad, CA) with random primers. Real-time polymerase chain reaction was performed on Rotor-Gene 3000 system (Corbett Research, Sydney, Australia) with thermal cycling conditions of 371C for 10 min, 951C for 5 min, followed by 50 cycles of 951C for 15 s, 601C for 20 s, and 681C for 20 s. The primer pairs and FAM-labelled MGB probes used were: TNF-a (forward: CTT ATC TAC TCC CAG GTT CTC T; reverse: TCT CCT GGT ATG AAA TGG CAA A; and probe: TCA CCC ACA CCG TCA G), iNOS (forward: TTC AGA GTC AAA TCC TAC CAA G; reverse: TGT GTT GTT GGG CTG GGA ATA; and probe: GAA AGA GGA AAA GGA CA), MCP-1 (forward: TGA CCC ATA AAT CTG AAG CTA A; reverse: GGC ATC ACA TTC CAA ATC ACA C; and probe: ACA ACC ACC TCA AGC AC), and transforming growth factor-b1 (forward: GGA CAC ACA GTA CAG CAA; reverse: GAC CCA CGT AGT AGA CGA T; and probe: ACA ACC AAC ACA ACC C). The relative amount of mRNA was calculated using comparative C t (DDC t ) method. All specific amplicons were normalized against 18S rRNA, which was amplified in the same reaction as an internal control using commercial assay reagents (Applied Biosystems, Scoresby, Vic., Australia).
Assessment of the humoral response in the anti-GBM disease model Kidney deposition of sheep IgG, rat IgG, and complement C3 was detected on snap-frozen cryostat sections by direct immunofluorescence staining with fluorescein isothiocyanate-conjugated antibodies. Semiquantification of the immunofluorescence staining was performed using an antibody titration method on blinded slides as described previously. 51 Circulating levels of rat IgG subtypes reactive with sheep IgG were quantified by a sandwich enzymelinked immunosorbent assay, as described previously. 51 
Statistical analysis
Data are presented as mean71 s.d. Analysis between groups of animals was performed by parametric analysis of variance using Tukey's post-test for multiple comparisons. Non-parametric data were analyzed by the Kruskal-Wallis analysis of variance by ranks using Dunn's post-test for multiple comparisons. Correlation analysis used the Pearson single correlation coefficient (GraphPad 4.0 Software, San Diego, CA).
